Skip to content
Shagandha®
  • About Shagandha®
    • Introduction
    • Traditional Significance
    • Chemistry
    • Why Shagandha®?
      • Complies with USP monograph
      • NON-GMO Project Verified
    • Benefits
  • Research
    • Preclinical
    • Clinical
    • Publications
  • IP Rights
    • Patents
    • Trademark Licence
  • About Sabinsa
    • Newsroom
      • Press Releases
      • Shagandha® Book
      • Ads
      • FAQs
  • Contact Us

Sabinsa granted US patent on LactoSpore® for IBS

Sabinsa has been granted a US patent on the company’s shelf-stable probiotic LactoSpore® (Bacillus coagulans MTCC 5856) for its use for therapeutic management of Irritable Bowel Syndrome (IBS).

Patent No. US9579352 claims a method for managing the symptoms associated with IBS including abdominal pain, bloating or visible distension of abdomen, constipation and loose stools, by orally administering a formulation comprising Bacillus coagulans MTCC 5856 (not less than 2 billion spores) as a dietary supplement along with regular treatment. LactoSpore® ameliorates the symptoms of IBS as seen in a recently published human clinical trial (Majeed et al. Nutrition Journal (2016) 15:21 DOI 10.1186/s12937-016-0140-6). In the study, LactoSpore® demonstrated efficacy in relieving clinical symptoms in IBS patients.

In 2016 Health Canada, the federal department that regulates the products that help the Canadian people maintain and improve their health, issued a Product License to Sabinsa for a significant health claim on LactoSpore®  Balance: “Helps relieve abdominal pain associated with IBS (Irritable Bowel Syndrome).”

“Sabinsa’s 136 patents demonstrate the continuous innovation process that Sabinsa proudly brings to its ingredients portfolio,” said Sabinsa Marketing Director Shaheen Majeed. “We deliver not only quality but efficacy as well, and this patent on LactoSpore® delivers on that focus.”

Back

About Sabinsa

Sabinsa is a manufacturer, supplier and marketer of herbal extracts, cosmeceuticals, minerals, dietary supplements and specialty fine chemicals for the nutritional, cosmetic, pharmaceutical and food industries.

Read More..

Headquarters

Sabinsa Corporation

20 Lake Drive 

East Windsor

NJ 08520, USA

 

Tel : +1 732 777 1111

Fax: +1 732 777 1443

info@sabinsa.com

Global Contact List

USAIndia
Utah, USAJapan
AustraliaPoland
BrasilKorea
CanadaSouth Africa
ChinaVietnam
Germany 

Contact us

    © 2025 Sabinsa. All Rights Reserved | Privacy Policy | Sitemap | Terms of Use | Disclaimer

    ×

    Disclaimer

    US-FDA: This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

    Usage disclaimer: The information pertaining to any marketing materials by Sabinsa, is for general purposes only. Users are urged to check the validity of patents if any, on any Sabinsa items for their intended use.

    EFSA: This statement has not been evaluated by the EFSA. This product is not intended to diagnose, treat, cure, or prevent any disease.

    Australia: Please note as an ingredient supplier the information contained in this website is for marketers of finished products formulations and is not intended as consumer advice. Marketers should ensure finished products are lawful and comply with the regulations of the countries in which these items are sold. Every care has been taken to ensure the accuracy of the information provided at the time of publication.